Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
PLoS One. 2009 Nov 18;4(11):e7887. doi: 10.1371/journal.pone.0007887.

Profiling critical cancer gene mutations in clinical tumor samples.

Author information

  • 1Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.

Erratum in

  • PLoS One. 2010;5(9). doi: 10.1371/annotation/613c7509-e4c9-42ac-82fb-fc504400d9e0.
  • PLoS One. 2010;5(9). doi: 10.1371/annotation/3a0c8fee-57ef-43ed-b6c2-55b503e6db5e.

Abstract

BACKGROUND:

Detection of critical cancer gene mutations in clinical tumor specimens may predict patient outcomes and inform treatment options; however, high-throughput mutation profiling remains underdeveloped as a diagnostic approach. We report the implementation of a genotyping and validation algorithm that enables robust tumor mutation profiling in the clinical setting.

METHODOLOGY:

We developed and implemented an optimized mutation profiling platform ("OncoMap") to interrogate approximately 400 mutations in 33 known oncogenes and tumor suppressors, many of which are known to predict response or resistance to targeted therapies. The performance of OncoMap was analyzed using DNA derived from both frozen and FFPE clinical material in a diverse set of cancer types. A subsequent in-depth analysis was conducted on histologically and clinically annotated pediatric gliomas. The sensitivity and specificity of OncoMap were 93.8% and 100% in fresh frozen tissue; and 89.3% and 99.4% in FFPE-derived DNA. We detected known mutations at the expected frequencies in common cancers, as well as novel mutations in adult and pediatric cancers that are likely to predict heightened response or resistance to existing or developmental cancer therapies. OncoMap profiles also support a new molecular stratification of pediatric low-grade gliomas based on BRAF mutations that may have immediate clinical impact.

CONCLUSIONS:

Our results demonstrate the clinical feasibility of high-throughput mutation profiling to query a large panel of "actionable" cancer gene mutations. In the future, this type of approach may be incorporated into both cancer epidemiologic studies and clinical decision making to specify the use of many targeted anticancer agents.

PMID:
19924296
[PubMed - indexed for MEDLINE]
PMCID:
PMC2774511
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk